Opioid use among patients with rheumatoid arthritis is prevalent, and while there is a small decrease in overall opioid use after tumor necrosis factor (TNF) inhibitor initiation, newly initiated opioid use after TNF inhibitor initiation may reflect an unmet need in pain management, say researchers writing in Rheumatology and Therapy this month.
IL-1 inhibition with anakinra was more effective than TNFi treatment for improving glycemic and inflammatory parameters in patients with rheumatoid arthritis and type 2 diabetes, say researchers writing in PLOS Medicine last month.
In this week's Rheumatology Network news roundup, we highlight advances in rheumatology research featured in recent issues of the New England Journal of Medicince, the journal Rheumatology and others. Among the most interesting findings was a study that highlights a link between antibiotic use and rheumatoid arthritis. Learn more in this slidesshow.
Patients with rheumatoid arthritis have a large comorbidity burden at the time of diagnosis, including chronic obstructive pulmonary disease (COPD), asthma and interstitial lung disease, but COPD is a particular concern, say researchers writing in Rheumatology this month.
Exposure to antibiotics increases the risk of developing rheumatoid arthritis, say researchers writing in the journal Rheumatology this month.
Patients with rheumatoid arthritis (RA) may be saddled with other health conditions ranging from mild allergies to cancer. Several studies have noted the increased incidence of mortality due to cardiovascular disease and infections. In this quiz, we focus on comorbidities associated with RA.
Patients with rheumatoid arthritis and diabetes saw greater improvement in blood glucose levels with sarilumab than adalimumab or placebo, shows a study spresented at Clinical Congress of Rheumatology West held in San Diego last month.
Long-term remission in rheumatoid arthritis is rare, but achieving rheumatoid arthritis remission even once can improve function and quality of life, researchers report.
In the September issue of The Lancet Rheumatology, Drs. Janet Pope and Peter C. Taylor review three historical game changers in rheumatoid arthritis treatment.
Parenteral methotrexate therapy is more successful than oral methotrexate in achieving optimal disease activity control in rheumatoid arthritis, with no increased adverse effects, say researchers writing in PLoS One this month.
Fluorescence optical imaging, which enables visualization of inflammation in the hands in rheumatic joint diseases, correlates with ultrasound as a validated and well-established imaging technique in daily rheumatological practice, say researchers writing in Arthritis Research & Therapy this month.
A study presented at CCR West found that tocilizumab displayed better biologic persistence compared with other biologics in patients with rheumatoid arthritis who previously received 1 or more other biologics.
Sheetal Desai, MD, AWARE investigator and assistant clinical professor of medicine at UC Irvine, discusses full 52-week results of study comparing 2 popular rheumatoid arthritis patients and what the observed safety profile means from a patient-centered perspective.
Aaron Broadwell, MD, rheumatologist and AWARE investigator, discusses his interpretation of the full 52-week results of the trial, which examined golimumab and infliximab in patients with rheumatoid arthritis in a real-world setting.
A post hoc analysis presented at CCR West found sarilumab outperformed adalimumab and placebo in HbA1c improvement in rheumatoid arthritis patients with diabetes.
A study examining a gene expression classifier from Scipher Medicine called PrismRA found the system could be used to identify at least half of the non-responders with at least 90% accuracy.
Sheetal Desai, MD, a rheumatologist and investigator of the ongoing AWARE trial, discusses her clinical takeaways from the 52-week results and the importance of real-world evidence.
AWARE Trial investigator Aaron Broadwell, MD, discusses what new data was presented during CCR West and how it differed from a previously presented interim analysis.
A new study from CCR West compared the JAK inhibitor therapy to competitors across a clinical trial program involving 5 pivotal phase 3 studies.
Maria Greenwald, MD, rheumatologist with Desert Medical Advances, discusses the results of a study she conducted that sought to identify the most effective ways a physician can advise a patient on how to save money on treatments.
Discussing the importance of implementing a multidisciplinary team when treating conditions that put patients at a predisposition for comorbidities with Rania Al Asmar, MBBS, of Marshall University.
Janet Pope, MD, professor of medicine at the University of Toronto, discusses whether she believes clinicians will ever transition away from DMARDs and biologics due to the high cost and what the alternatives are for those patients.
Elena Myasoedova, MD, of the Mayo Clinic, discusses the results of a study examining the incidence rates of cardiovascular disease in patients with rheumatoid arthritis across 3 decades.
Rania Al Asmar, MBBS, discusses a study she led and authored that examined prevalence and characteristics of patients with rheumatoid arthritis who later developed coronary artery disease.
Jack Stacy, MSIV, of University of North Dakota, discusses a study he co-authored and presented at CCR West examining the use of low-dose prednisone to induce remission in patients with rheumatoid arthritis.
